Tide Laboratories announces a strategic collaboration with the Max Planck Institute for peptide drug discovery research.
Tide Laboratories is proud to announce a strategic research collaboration with the Max Planck Institute for Biochemistry, one of Europe's leading institutions in molecular biology and biochemistry.
Collaboration Scope
The partnership focuses on: - Developing novel peptide therapeutics for neurodegenerative diseases - Advancing analytical methods for peptide characterization - Training and knowledge exchange programs for researchers - Co-publishing research findings
Research Focus
The collaboration will address key challenges in peptide drug development: - Blood-brain barrier penetration for CNS-targeted peptides - Strategies to enhance oral bioavailability - Long-acting peptide formulation technologies - Targeted delivery systems using peptide conjugates
Resource Commitment
Both institutions are committing significant resources: - Tide Laboratories: Custom synthesis capabilities, analytical support, and scale-up expertise - Max Planck Institute: Biological screening platforms, in vivo models, and clinical insights
Timeline
- Initial phase: 2 years (2026-2028)
- Focus: Proof-of-concept studies for 3 candidate molecules
- Milestone reviews: Every 6 months
- Extend based on results
Expected Outcomes
This collaboration aims to: - Accelerate discovery of novel peptide therapeutics - Develop innovative synthesis and formulation technologies - Train the next generation of peptide scientists - Publish high-impact research in peer-reviewed journals
Quote from Leadership
"This partnership marks a major milestone in our mission to advance peptide science," said Dr. David Chen, CEO of Tide Laboratories. "By combining our synthesis expertise with Max Planck's biological research capabilities, we can accelerate the development of transformative therapies."
We look forward to sharing progress updates as this exciting collaboration unfolds.
